Background Investigations into the rivaroxaban response from the perspective of genetic
variation have been relatively recent and wide in scope, whereas there is no consensus on …

Introduction. Pharmacogenetics is a potential approach that can be applied to decline the
burden of rivaroxaban's ADRs. The current systematic review and meta-analysis aim to …

Purpose This study aimed to explore the pharmacogenetic variability associated with the
pharmacokinetics (PK) and pharmacodynamics (PD) of rivaroxaban in healthy Chinese …

Non-vitamin K antagonist oral anticoagulants' interindividual trough concentration variability
affects efficacy and safety, especially in bleeding events. Rivaroxaban is metabolised via …

Rivaroxaban is one of the new oral anticoagulants (NOAC) for preventing stroke and
systemic embolism in patients with non-valvular atrial fibrillation. It has clear …

Background and Objectives: Genetic data on the pharmacokinetics of rivaroxaban and
identification of factors that affect its biotransformation, distribution, and excretion will allow …

Objective The study of ABCB1 and CYP3A4/3A5 gene polymorphism genes is promising in
terms of their influence on prothrombin time variability, the residual equilibrium …

Background The influence of genetic factors on the pharmacokinetics and clinical outcomes
of rivaroxaban in patients with non-valvular atrial fibrillation (NVAF) is poorly understood …

Hemorrhage events occur most frequently in anticoagulant therapy for non‐valvular atrial
fibrillation (NVAF). Rivaroxaban is used widely for routine anticoagulation care. Genetic …

Background Serious bleeding events have been frequently described in patients taking
direct oral anticoagulants (DOAC). In secondary analyses of phase 3 trials, DOAC plasma …